<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39284068</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>39</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2-specific CD8<sup>+</sup> T cells from people with long COVID establish and maintain effector phenotype and key TCR signatures over 2 years.</ArticleTitle><Pagination><StartPage>e2411428121</StartPage><MedlinePgn>e2411428121</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2411428121</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2411428121</ELocationID><Abstract><AbstractText>Long COVID occurs in a small but important minority of patients following COVID-19, reducing quality of life and contributing to healthcare burden. Although research into underlying mechanisms is evolving, immunity is understudied. SARS-CoV-2-specific T cell responses are of key importance for viral clearance and COVID-19 recovery. However, in long COVID, the establishment and persistence of SARS-CoV-2-specific T cells are far from clear, especially beyond 12 mo postinfection and postvaccination. We defined ex vivo antigen-specific B cell and T cell responses and their T cell receptors (TCR) repertoires across 2 y postinfection in people with long COVID. Using 13 SARS-CoV-2 peptide-HLA tetramers, spanning 11 HLA allotypes, as well as spike and nucleocapsid probes, we tracked SARS-CoV-2-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells and B-cells in individuals from their first SARS-CoV-2 infection through primary vaccination over 24 mo. The frequencies of ORF1a- and nucleocapsid-specific T cells and B cells remained stable over 24 mo. Spike-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells and B cells were boosted by SARS-CoV-2 vaccination, indicating immunization, in fully recovered and people with long COVID, altered the immunodominance hierarchy of SARS-CoV-2 T cell epitopes. Meanwhile, influenza-specific CD8<sup>+</sup> T cells were stable across 24 mo, suggesting no bystander-activation. Compared to total T cell populations, SARS-CoV-2-specific T cells were enriched for central memory phenotype, although the proportion of central memory T cells decreased following acute illness. Importantly, TCR repertoire composition was maintained throughout long COVID, including postvaccination, to 2 y postinfection. Overall, we defined ex vivo SARS-CoV-2-specific B cells and T cells to understand primary and recall responses, providing key insights into antigen-specific responses in people with long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Rowntree</LastName><ForeName>Louise C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-0649-5089</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Audsley</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Lilith F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McQuilten</LastName><ForeName>Hayley A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagen</LastName><ForeName>Ruth R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaurasia</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-3755-159X</Identifier><AffiliationInfo><Affiliation>Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Littler</LastName><ForeName>Dene R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0001-5904-1905</Identifier><AffiliationInfo><Affiliation>Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Hyon-Xhi</ForeName><Initials>HX</Initials><Identifier Source="ORCID">0000-0003-1064-3934</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murdiyarso</LastName><ForeName>Lydia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habel</LastName><ForeName>Jennifer R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foo</LastName><ForeName>Isabelle J H</ForeName><Initials>IJH</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wuji</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ten Berge</LastName><ForeName>Elizabeth R V</ForeName><Initials>ERV</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganesh</LastName><ForeName>Hanujah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaewpreedee</LastName><ForeName>Prathanporn</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>HKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kelly W K</ForeName><Initials>KWK</Initials><AffiliationInfo><Affiliation>HKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Samuel M S</ForeName><Initials>SMS</Initials><AffiliationInfo><Affiliation>Division of Public Health Laboratory Sciences, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Janette S Y</ForeName><Initials>JSY</Initials><AffiliationInfo><Affiliation>Division of Transplantation and Immunogenetics, Department of Pathology, Queen Mary Hospital, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayasinghe</LastName><ForeName>Dhilshan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Infection &amp; Immunity Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3083, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe University, Bundoora, VIC 3083, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gras</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infection &amp; Immunity Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3083, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe University, Bundoora, VIC 3083, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juno</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheatley</LastName><ForeName>Adam K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0002-5593-9387</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-8539-4891</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossjohn</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2020-7522</Identifier><AffiliationInfo><Affiliation>Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4XN, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Allen C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash Infectious Diseases, Monash Health and School of Clinical Sciences, Monash University, Clayton, VIC 3168, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotsimbos</LastName><ForeName>Tom C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, The Alfred Hospital, Melbourne, VIC 3004, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Central Clinical School, The Alfred Hospital, Monash University, Melbourne, VIC 3004, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trubiano</LastName><ForeName>Jason A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Centre for Infections in Cancer, Peter McCallum Cancer Centre, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (Austin Health), University of Melbourne, Heidelberg, VIC 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Natasha E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, VIC 3084, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Critical Care, University of Melbourne, Parkville, VIC 3000, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Data Analytics Research and Evaluation Centre, Austin Health and University of Melbourne, Heidelberg, VIC 3084, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang Chan</LastName><ForeName>Ken Ka</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>David S C</ForeName><Initials>DSC</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peiris</LastName><ForeName>Malik</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8217-5995</Identifier><AffiliationInfo><Affiliation>HKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Public Health Laboratory Sciences, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Immunology and Infection, Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Leo L M</ForeName><Initials>LLM</Initials><Identifier Source="ORCID">0000-0002-9101-7953</Identifier><AffiliationInfo><Affiliation>HKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Public Health Laboratory Sciences, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Immunology and Infection, Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewin</LastName><ForeName>Sharon R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Victorian Infectious Diseases Service, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, Alfred Hospital and Monash University, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Doherty</LastName><ForeName>Peter C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Thevarajan</LastName><ForeName>Irani</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Victorian Infectious Diseases Service, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Valkenburg</LastName><ForeName>Sophie A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HKU-Pasteur Research Pole, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kedzierska</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-6141-335X</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nguyen</LastName><ForeName>Thi H O</ForeName><Initials>THO</Initials><Identifier Source="ORCID">0000-0002-9294-7693</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1173871</GrantID><Agency>DHAC | National Health and Medical Research Council (NHMRC)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086462">Coronavirus Nucleocapsid Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="Y">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011948" MajorTopicYN="Y">Receptors, Antigen, T-Cell</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086462" MajorTopicYN="N">Coronavirus Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 epitopes</Keyword><Keyword MajorTopicYN="N">T cell receptors</Keyword><Keyword MajorTopicYN="N">T cells</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>Competing interests statement:Hayley McQuilten consults for Ena Respiratory.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>10</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>16</Day><Hour>15</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39284068</ArticleId><ArticleId IdType="pmc">PMC11441481</ArticleId><ArticleId IdType="doi">10.1073/pnas.2411428121</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bowe B., Xie Y., Al-Aly Z., Postacute sequelae of COVID-19 at 2 years. Nat. Med. 29, 2347&#x2013;2357 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Su S., et al. , Epidemiology, clinical presentation, pathophysiology, and management of long COVID: An update. Mol. Psychiatry 28, 4056&#x2013;4069 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37491461</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelman B., et al. , Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat. Commun. 15, 17 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10766651</ArticleId><ArticleId IdType="pubmed">38177128</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H. E., et al. , Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMed. 38, 101019 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., et al. , Characterising long COVID: A living systematic review. BMJ Glob Health 6, e005427 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., et al. , Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Network Open 4, e2128568 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie C. E., et al. , Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat. Commun. 13, 5663 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozonoff A., et al. , Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: Results from the IMPACC study. Nat. Commun. 15, 216 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10764789</ArticleId><ArticleId IdType="pubmed">38172101</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney L. L., et al. , Corrigendum to "The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis". eClinicalMed. 59, 101959 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10115131</ArticleId><ArticleId IdType="pubmed">37096187</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., et al. , Health outcomes in people 2 y after surviving hospitalisation with COVID-19: A longitudinal cohort study. The Lancet Respir. Med. 10, 863&#x2013;876 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Joy G., et al. , Prospective case-control study of cardiovascular abnormalities six months following mild COVID-19 in healthcare workers. JACC Cardiovasc Imaging 14, 2155&#x2013;2166 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8105493</ArticleId><ArticleId IdType="pubmed">33975819</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann V. O., et al. , Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat. Med. 28, 2117&#x2013;2123 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556300</ArticleId><ArticleId IdType="pubmed">36064600</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G., et al. , SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 604, 697&#x2013;707 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J. E., Okyay R. A., Licht W. E., Hurley D. J., Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens 10, 763 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M. J., et al. , Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Invest. 133, e163669 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., et al. , Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 71, 544&#x2013;552 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A. D., et al. , SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat. Immunol. 24, 1616&#x2013;1627 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann D. M., Whettlock E. M., Liu S., Arachchillage D. J., Boyton R. J., The immunology of long COVID. Nat. Rev. Immunol. 23, 618&#x2013;634 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew F., et al. , Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nat. Immunol. 25, 607&#x2013;621 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11003868</ArticleId><ArticleId IdType="pubmed">38589621</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J., et al. , Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: A longitudinal study. J. Clin. Immunol. 41, 1490&#x2013;1501 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X., et al. , Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndrome. JCI Insight 7, e156713 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9310538</ArticleId><ArticleId IdType="pubmed">35801588</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia-Hasler C., et al. , Persistent complement dysregulation with signs of thromboinflammation in active long Covid. Science 383, eadg7942 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38236961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bange E. M., et al. , CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat. Med. 27, 1280&#x2013;1289 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8291091</ArticleId><ArticleId IdType="pubmed">34017137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedzierska K., Thomas P. G., Count on us: T cells in SARS-CoV-2 infection and vaccination. Cell Rep. Med. 3, 100562 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8872824</ArticleId><ArticleId IdType="pubmed">35474748</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., et al. , An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat. Immunol. 23, 50&#x2013;61 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8709787</ArticleId><ArticleId IdType="pubmed">34853448</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P., Tahmasebi N., Gant V., Gupta R., Long COVID following mild SARS-CoV-2 infection: Characteristic T cell alterations and response to antihistamines. J. Investig. Med. 70, 61&#x2013;67 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiech M., et al. , Remodeling of T cell dynamics during long COVID Is dependent on severity of SARS-CoV-2 infection. Front. Immunol. 13, 886431 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9226563</ArticleId><ArticleId IdType="pubmed">35757700</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy L., et al. , Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 nucleocapsid protein. Front. Immunol. 14, 1155770 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10258318</ArticleId><ArticleId IdType="pubmed">37313412</ArticleId></ArticleIdList></Reference><Reference><Citation>Files J. K., et al. , Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI Insight 6, e151544 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., et al. , Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 23, 210&#x2013;216 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K., et al. , Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat. Immunol. 25, 218&#x2013;225 (2024), 10.1038/s41590-023-01724-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01724-6</ArticleId><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., et al. , Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection. Nat. Commun. 15, 3315 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11024141</ArticleId><ArticleId IdType="pubmed">38632311</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y., Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 28, 1461&#x2013;1467 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., et al. , Trajectory of long covid symptoms after covid-19 vaccination: Community based cohort study. BMJ 377, e069676 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain W. D., et al. , The impact of COVID vaccination on symptoms of long COVID: An international survey of people with lived experience of long COVID. Vaccines (Basel) 10, 652 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynberg E., et al. , The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study. Vaccine 40, 4424&#x2013;4431 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="pubmed">35725782</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization, Post COVID-19 condition (long COVID). in https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition#:~:text=Definitionmonths%20with%20no%20other%20explanation (2022).</Citation></Reference><Reference><Citation>Habel J. R., et al. , Suboptimal SARS-CoV-2&#x2212;specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype. Proc. Natl. Acad. Sci. U.S.A. 117, 24384&#x2013;24391 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7533701</ArticleId><ArticleId IdType="pubmed">32913053</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T. H. O., et al. , CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity 54, 1066&#x2013;1082.e65 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049468</ArticleId><ArticleId IdType="pubmed">33951417</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowntree L. C., et al. , SARS-CoV-2-specific T cell memory with common TCR&#x3b1;&#x3b2; motifs is established in unvaccinated children who seroconvert after infection. Immunity 55, 1299&#x2013;1315.e94 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9174177</ArticleId><ArticleId IdType="pubmed">35750048</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T. H. O., et al. , Robust SARS-CoV-2 T cell responses with common TCR&#x3b1;&#x3b2; motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells. Cell Rep. Med. 4, 101017 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10040362</ArticleId><ArticleId IdType="pubmed">37030296</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudd P. A., et al. , SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 185, 603&#x2013;613.e5 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8695127</ArticleId><ArticleId IdType="pubmed">35026152</ArticleId></ArticleIdList></Reference><Reference><Citation>Wragg K.M., et al. , Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+T cell memory. Nat Immunol. 23, 768&#x2013;780 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35314848</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervina A. A., et al. , SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nat. Immunol. 23, 781&#x2013;790 (2022), 10.1038/s41590-022-01184-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01184-4</ArticleId><ArticleId IdType="pmc">PMC9106845</ArticleId><ArticleId IdType="pubmed">35383307</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., et al. , Clonally diverse CD38+HLA-DR+CD8+ T cells persist during fatal H7N9 disease. Nat. Commun. 9, 824 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5827521</ArticleId><ArticleId IdType="pubmed">29483513</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M., et al. , Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep. Med. 2, 100208 (2021), 10.1016/j.xcrm.2021.100208,100208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100208,100208</ArticleId><ArticleId IdType="pmc">PMC7862905</ArticleId><ArticleId IdType="pubmed">33564749</ArticleId></ArticleIdList></Reference><Reference><Citation>McLane L. M., Abdel-Hakeem M. S., Wherry E. J., CD8 T cell exhaustion during chronic viral infection and cancer. Ann. Rev. Immunol. 37, 457&#x2013;495 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30676822</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncharov M., et al. , VDJdb in the pandemic era: A compendium of T cell receptors specific for SARS-CoV-2. Nat. Methods 19, 1017&#x2013;1019 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35970936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowntree L. C., et al. , SARS-CoV-2-specific CD8+ T cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph. Immunol. Cell Biol. 99, 990&#x2013;1000 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8242669</ArticleId><ArticleId IdType="pubmed">34086357</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T. H. O., Rowntree L. C., Chua B. Y., Thwaites R. S., Kedzierska K., Defining the balance between optimal immunity and immunopathology in influenza virus infection. Nat. Rev. Immunol. (2024), 10.1038/s41577-024-01029-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-024-01029-1</ArticleId><ArticleId IdType="pubmed">38698083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., et al. , Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8+ T cells. Nat. Commun. 6, 6833 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479016</ArticleId><ArticleId IdType="pubmed">25967273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang E., et al. Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments. Gut. 73, 712&#x2013;714 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36878683</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., et al. , Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities. Nat. Immunol. 24, 966&#x2013;978 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10232372</ArticleId><ArticleId IdType="pubmed">37248417</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T. H. O., SARS-CoV-2-specific CD8+ T cells from people with long COVID establish and maintain effector phenotype and key TCR signatures over 2 years. Mendeley Data. 10.17632/ffw3jrbdcb.1. Deposited 23 July 2024.</Citation><ArticleIdList><ArticleId IdType="doi">10.17632/ffw3jrbdcb.1</ArticleId><ArticleId IdType="pmc">PMC11441481</ArticleId><ArticleId IdType="pubmed">39284068</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>